July 18-20 2017 | Boston

Register by Friday, June 23 to save up to $500

 

Workshop A
Tuesday July 18, 2017

08.30 - 11.30

Characterization of PDX Models in the Context of Humanized Mice


Workshop Leader: Vinagolu Rajasekhar, Senior Research Scientist, Memorial Sloan Kettering Cancer Center


 

The following questions will be answered:

 

  • What are the current limitations with PDX models when studying the tumor microenvironment?
  • What methodologies are being used to develop humanized mice models from PDX models?
  • How is the development of humanized mice from PDX models overcoming these limitations?
  • What technical challenges need overcoming to harness these models for therapeutic development?

Vinagolu Rajasekhar, Senior Research Scientist, Memorial Sloan Kettering Cancer Center

Vinagolu Rajasekhar photo

Dr. Vinagolu K. Rajasekhar, a Senior Research Scientist at the Memorial Sloan-Kettering Cancer Center, has been developing humanized patient derived xenograft (PDX) models of metastatic cancers in the institutional collaboration with Dr. John Healey, the Chief of Orthopedics Service.  Dr. Rajasekhar has also purified cancer stem cells (CSCs) from human prostate cancer PDXs, discovered a novel set of biomarkers for the tumor driving cells, and delineated a clinically relevant functional signaling pathway in prostate cancer (www.Genomeweb.com). This study unveils a new direction to live bio-bank patient CSC-derived xenograft (PDXCSC) models of human tumors, which form an excellent and replenishable resource for understanding patient personalized signaling cross-talks between the CSCs and their specific microenvironment as well as for therapeutic testing and co-clinical trials.

Workshop B
Tuesday July 18, 2017

12.00 - 15.00

Characterizing Preclinical Models for Advancing Cell Therapies


Workshop Leader: Saad Kenderian, Assistant Professor of Medicine & Oncology, Mayo Clinic


 

The following questions will be addressed:

 

  • How is the industry using humanized mice models for cell therapy preclinical studies?
  • What are the limitations in the current models for developing ex vivo therapies?
  • What strategies are the industry developing to test CAR-T therapies in preclinical models?
  • What developments are required to advance in vivo models for the preclinical testing of ex vivo therapies?

Saad Kenderian, Assistant Professor of Medicine & Oncology, Mayo Clinic

Saad Kenderian

Saad S. Kenderian, MD is a senior associate consultant in the Division of Hematology at the Mayo Clinic. He holds the academic rank of Assistant Professor of Medicine and Oncology, Mayo Clinic College of Medicine. After completing a combined fellowship in hematology and medical oncology, he joined the Division of Hematology at Mayo, received the Mayo Scholar award and joined the Translational Research Program of the University of Pennsylvania as a Mayo Scholar, where he worked in T cell immunotherapy for over two years. He returned to the Mayo Clinic in early 2016. Dr. Kenderian has been honored with numerous awards during his training and career. He is a member of the American Society of Hematology, American Society for Blood and Marrow Transplantation, American Association for Cancer Research. Dr. Kenderian has authored or co-authored more than 25 articles in peer-reviewed journals and he holds several patents in the field of engineered T cell therapy.

Workshop C
Tuesday July 18, 2017

15.30 - 18.30

Optimizing Humanized Mice Models for the Advancement of Cancer Immunotherapies


Workshop Leader: Michael Brehm, Associate Professor, The Robert and Sandra Glass Term Chair , in Diabetes, University of Massachusetts Medical School Workshop Leader: Barbara Joyce-Shaikh, Associate Principal Scientist, Immunoncology, Merck Research Laboratories


 

The following areas will be discussed:

 

  • What are the current methodologies to develop humanized mice models?
  • What are the limitations of humanized mice models in preclinical practice?
  • Case studies on the use of humanized mice models for IO preclinical studies
  • What future developments are required to utilize humanized mice routinely?

Michael Brehm, Associate Professor, The Robert and Sandra Glass Term Chair , in Diabetes, University of Massachusetts Medical School

Michael Brehm, Ph.D.

Dr. Brehm received his Ph.D. from the Department of Microbiology and Immunology at the Pennsylvania State University College of Medicine. He is currently an Assistant Professor in the Program in Molecular Medicine at the University of Massachusetts Medical School and a member of the UMass Diabetes Center of Excellence. Dr. Brehm’s research program is focused on understanding how human effector T cells are regulated, and his laboratory is actively using “humanized” mice to model human T cell responses. Dr. Brehm has published over 80 manuscripts and reviews and is supported by funding from the JDRF, NIAID, NIDDK and the Helmsley Charitable Trust.

Barbara Joyce-Shaikh, Associate Principal Scientist, Immunoncology, Merck Research Laboratories

Canon 5D Mark III w/ 135mm f/2L USM

Barbara Joyce-Shaikh completed her B.S in with Molecular Biology at San Jose State University. She has more than 20 years of biotech industry experience specializing in translational systems of immune function and immunoncology. Her work has contributed several patents as well as medical literature published in journals such as Nature, Immunity, Nature Medicine, and the Journal of Experimental Medicine. She is currently a Project Leader in the Discovery Immunoncology group at Merck Research Laboratories, Palo Alto (Formerly DNAX Research Institute). Her current research utilizes humanized mouse systems and is focused on understanding how tumor stroma and immune cell interactions can be altered with novel immunomodulatory agents in different cancers.